The win is on the boring stuff. Past about five regular medications the math turns against you: interactions multiply, and the older body clears drugs slowly. The Beers list names roughly a hundred whose risk-benefit ratio flips after 65 1. Old antihistamines, some antidepressants, and bladder and sleep drugs block a brain chemical you need for memory; taken daily for a few years they raise dementia risk about 50% 2. Sedatives roughly double falls, the top cause of accidental death after 65 3.
But only the right drugs count. Mortality drops when clinicians target specific bad drugs; when trials just cut total pill count, the benefit vanishes 4. Fewer pills isn't the win. Fewer of the wrong pills is.
Here's the part most people get wrong. A lot of long-term drugs train the body to expect them. Stop cold and it overcorrects: the stomach floods with acid after an acid blocker comes off, the nose blocks worse after a decongestant spray stops. That rebound is pharmacology, and it fades over a few weeks if you taper. People who don't know this feel the symptom, assume the disease is back, and restart the drug for life. Stopping well is most of the skill.
Book a medication review with a pharmacist (or your primary doctor). Bring every bottle: prescriptions, over-the-counter, supplements, eye drops. For each drug, five questions 5:
Most you can just stop. Four fight back and need a taper: acid blockers (step down over weeks; an antacid bridges the heartburn) 6, decongestant sprays (swap for a steroid spray and saline) 7, SSRIs and SNRIs (slow exponential cuts) 8, and beta-blockers (halve every few days) 1. Repeat yearly and after any hospital stay 9.
The fast wins land in the first month, once the taper window passes. Afternoons stop being a dead zone; the drive home doesn't feel like fog. In one cohort of older adults averaging four drugs stopped apiece, 88% felt better afterward and only 2% regretted it 10. The slow wins you never notice: the fall that doesn't happen, the hospital stay that never comes, the mortality edge over the years 4.
The fine print — when to skip it, and what people get wrong
"See, I really did need it." After an 8-week acid blocker, healthy volunteers with no reflux at all develop reflux when they stop — nearly half of them 11. That's rebound, not your disease returning; it clears in a few weeks. Some drugs do belong on the list forever: statins after a heart attack, blood thinners for atrial fibrillation, thyroid replacement.
Never stop these cold on your own: beta-blockers with known heart disease (rebound can trigger a heart attack), long-term steroids (adrenal crash), antiepileptics (seizures), anticoagulants in atrial fibrillation (stroke), and benzodiazepines after daily use (seizures). Anything taken daily for weeks deserves a taper conversation, not a clean stop.
Where it goes sideways: stopping with no follow-up, so rebound at week 2–4 makes you panic and restart — book check-ins first. Or the specialist quietly restarts what the pharmacist stopped, so send the plan to everyone in writing.
- 1American Geriatrics Society Beers Criteria Update Expert Panel (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. link
- 2Coupland CAC, Hill T, Dening T et al. (2019). Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Internal Medicine. link
- 3Seppala LJ, Petrovic M, Ryg J et al. (2021). STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age and Ageing. link
- 4Page AT, Clifford RM, Potter K et al. (2016). The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. British Journal of Clinical Pharmacology. link
- 5Scott IA, Hilmer SN, Reeve E et al. (2015). Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Medicine. link
- 6Farrell B, Pottie K, Thompson W et al. (2017). Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Canadian Family Physician. link
- 7Wilcock J, Bird L (2018). Rhinitis medicamentosa: causes, diagnosis and treatment. Prescriber. link
- 8Horowitz MA, Taylor D (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. link
- 9O'Mahony D, Cherubini A, Guiteras AR et al. (2023). STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. European Geriatric Medicine. link
- 10Garfinkel D, Mangin D (2010). Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Archives of Internal Medicine. link
- 11Reimer C, Søndergaard B, Hilsted L, Bytzer P (2009). Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. link
დაკავშირებული სახელმძღვანელოში (9)
- — An anticholinergic load is one of the top things a yearly medication review should hunt for and unwind.
- — While reviewing the list, flag narrow-margin drugs (thyroid, warfarin, anti-seizure) — manufacturer swaps there need a level recheck.
- — Both run off the same single list of everything you take — bring it to the annual review.
- — The annual medication review is when to flag whether your drug list collides with grapefruit or this herb.
- — Deciding whether a pill still earns its place means knowing how many people it actually helps — number-needed-to-treat is the tool for that.
- — An annual med review is where an ear-toxic drug you no longer need gets caught and dropped before it touches your hearing.
- — An accurate med list is what makes a yearly medication review possible — the record feeds the audit.
- — Bringing your full medication list to the visit is what makes the once-a-year audit of what you can stop actually happen.
- — A PPI started years ago and never stopped is the textbook case for an annual medication review.
The Annual Medication Review
Annual review appointment plus 4–12 weeks of monitored taper for any rebound-producing drug stopped; not daily ongoing willpower, but the taper window requires attention. Patient bears the rebound-symptom burden during weeks 2–8 of a PPI or SSRI taper.
Multiple international guidelines (Beers 2023, STOPP/START v3 2023, Bruyère/deprescribing.org class-specific guidelines), Page et al. 2016 meta-analysis, multiple RCTs (D-PRESCRIBE, EMPOWER, OPERAM). Process-level outcomes consistently positive; hard-outcome signal positive in targeted trials but null in OPERAM — prevents a 5.
Removing the side-effect burden of inappropriate long-term medications produces clear functional improvement within weeks; Garfinkel & Mangin 2010 reported 88% global improvement after a mean of 4.4 drugs stopped in community-dwelling older adults.
Page et al. 2016 meta-analysis (132 papers, 34,143 participants) found targeted deprescribing reduced all-cause mortality (OR 0.32, 95% CI 0.17–0.60); generic polypharmacy reduction did not. OPERAM 2021 was null on drug-related readmissions, so the hard-outcome case is good but not dominant.
Removing sedating drugs (benzodiazepines, anticholinergic antihistamines, opioids, some beta-blockers) produces a clear less-fatigue effect mediated by reduced CNS suppression; STOPPFall and Beers anchor the drug list.
Anticholinergic burden correlates dose-dependently with cognitive impairment and incident dementia (Coupland et al. 2019, adjusted OR 1.49 at high cumulative exposure); reducing CNS-active polypharmacy (13.9% of community-dwelling adults with dementia in Maust et al. 2021) is a clear cognitive lift.
Net small-positive: removing diuretics reduces nocturia, removing chronic hypnotics restores normal sleep architecture after a withdrawal window, but no dominant signal on sleep quality per se.
Beta-blockers and several anticholinergics have depressive side-effect profiles; chronic benzodiazepine use produces interdose anxiety. Off-label SSRI deprescribing in patients who no longer need them removes blunting. Real but modest mood signal, with acute taper risk in the SSRI subset.